Abecma’s US Revenue Continues to Increase; DARIC33’s Data to Be Presented at ASGCT 2023; Manufacturing Capacity Ramping Up; 2seventy bio’s Q1 2023 Earnings Call Summary
On Wednesday, May 3, 2seventy bio held its Q1 2023 earnings call (press release) highlighting Abecma’s (BMS / 2seventy’s BCMA CAR-T) significant revenue increase. Moreover, management confirmed that early clinical data from DARIC33’s Ph1 PLAT-08 trial in r/r AML will be presented at ASGCT 2023 (May 16-20). Below, Celltelligence provides insights on 2seventy bio’s strategy to improve manufacturing capacity with a newly FDA-approved viral vector manufacturing suite, while discussing the main clinical milestones achieved by the assets in the pipeline.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.